RMTG Announces Academic Collaboration Between ISSCA and the University of Buenos Aires
Proposed academic endorsement of postgraduate fellowship and physician certification programs would mark a major milestone in ISSCA’s international education platform.
MIAMI, FL — [RELEASE DATE] — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”) announced a collaboration between its physician education division, the International Society for Stem Cell Application (ISSCA), and the University of Buenos Aires (UBA), one of Latin America’s most established academic institutions.
Under the collaboration as described by management, ISSCA’s postgraduate Fellowship in Cell Therapy and Tissue Engineering, together with designated physician certification and training programs, are intended to receive academic endorsement from UBA, subject to the scope and terms of the institutions’ agreement.
Founded in 2009, ISSCA has developed an international platform for physician education in regenerative medicine, cellular therapies and tissue engineering, training thousands of medical professionals in more than 40 countries.
“This collaboration represents one of the most meaningful academic milestones in ISSCA’s history,” said Emiliano Herrera, Director of ISSCA. “For more than 17 years, our organization has focused on advancing physician education in regenerative medicine. Recognition by an institution with the academic tradition of the University of Buenos Aires is a powerful acknowledgment of that work.”
The initiative is intended to strengthen the academic profile of ISSCA’s postgraduate and continuing education offerings, enhance value for participating physicians and support expansion of its international education programs.
“For our physicians, this adds another dimension of academic recognition to the programs we have built over nearly two decades,” Herrera added. “We believe it can open an important new chapter in ISSCA’s global development.”
Any university endorsement will apply only to programs expressly identified in the finalized agreement and does not itself confer a UBA degree, professional license or regulatory authorization.
About the Operating Division
The International Society for Stem Cell Application (ISSCA) is the physician education division of Global Stem Cells Group, providing postgraduate training, certifications, conferences and practical programs in regenerative medicine. www.issca.com
About RMTG
Regenerative Medical Technology Group, Inc. (OTC: RMTG) operates an integrated regenerative medicine platform through Global Stem Cells Group and its specialized businesses. www.rmtg.com
Forward-Looking Statements
This press release contains forward-looking statements under applicable securities laws, including statements regarding anticipated growth, revenues, product adoption, academic collaboration, product introductions and geographic expansion. Actual results may differ materially due to regulatory developments, operational execution, market acceptance, competition and other risks. These statements are not guarantees of future performance. The Company undertakes no duty to update them except as required by law.
Investor Relations
Regenerative Medical Technology Group, Inc. | OTC: RMTG | www.rmtg.com |
- Published in Press Releases
RMTG’s Cellgenic Accelerates Global Physician Workshop Expansion to Support Biologics Adoption and International Sales
International training programs bring advanced regenerative medicine education directly to physicians across Latin America and the Middle East.
MIAMI, FL — November 6, 2026 — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”) announced that Cellgenic, its advanced biologics and regenerative therapeutics division operating through Global Stem Cells Group, is accelerating its international expansion through a series of physician-focused workshops across key markets.
The initiative combines biologics commercialization with direct physician education, practical training and ongoing professional support. Workshops are underway or scheduled across Cancun, Peru, Paraguay, Colombia, Brazil and Argentina, with Dubai and additional markets planned.
Designed for groups of approximately 50 physicians, the workshops generally run one to two days. Expert-led sessions address peptides, cellular therapies, exosomes, clinical considerations, dosing principles, combination strategies, protocol development and appropriate use under applicable regulatory requirements.
“Cellgenic is entering a very exciting phase of international expansion,” said Sarah Barroso, CEO of Cellgenic. “Physicians need more than access to advanced biologics. They need knowledge, confidence and ongoing technical guidance. By bringing that expertise directly into their markets, we believe we can strengthen customer loyalty, accelerate product adoption and support sustained commercial growth.”
Management expects the initiative to improve physician onboarding, deepen existing customer relationships and create opportunities for repeat purchasing and expanded sales of Cellgenic products. These outcomes remain subject to execution, physician demand and market conditions.
“We are building a worldwide community of physicians who understand our technologies and see Cellgenic as a long-term partner,” Barroso added. “We expect that community to create additional opportunities as we continue expanding our workshop calendar.”
The Company expects to add further physician education programs and international markets during 2027.
About the Operating Division
Cellgenic is the advanced biologics and regenerative medicine commercialization division of Global Stem Cells Group, focused on cellular technologies, regenerative products and physician engagement. www.cellgenic.com
About RMTG
Regenerative Medical Technology Group, Inc. (OTC: RMTG) operates an integrated regenerative medicine platform through Global Stem Cells Group and its specialized businesses. www.rmtg.com
Forward-Looking Statements
This press release contains forward-looking statements under applicable securities laws, including statements regarding anticipated growth, revenues, product adoption, academic collaboration, product introductions and geographic expansion. Actual results may differ materially due to regulatory developments, operational execution, market acceptance, competition and other risks. These statements are not guarantees of future performance. The Company undertakes no duty to update them except as required by law.
Investor Relations
Regenerative Medical Technology Group, Inc. | OTC: RMTG | www.rmtg.com |
- Published in Press Releases
RMTG’s Cellgenic Announces Planned Launch of Autologous Fibroblast Technology in Argentina
A December 12 physician event in Buenos Aires will introduce a new aesthetic cellular technology initiative within Cellgenic’s expanding regenerative medicine portfolio.
MIAMI, FL — November 6, 2026 — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”) announced that its advanced biologics division, Cellgenic, is preparing to introduce an autologous fibroblast product developed through its laboratory operations in Buenos Aires, Argentina.
The initiative expands Cellgenic’s work in cellular technologies for aesthetic medicine and complements its existing portfolio spanning regenerative biologics, stem cell technologies, exosomes and peptides.
Autologous fibroblast technology involves cells derived from an individual’s own tissue and is an area of research and development for potential aesthetic and tissue applications. Any clinical commercialization or use will depend on the applicable regulatory authorizations, medical requirements and product-specific evidence.
Cellgenic plans to formally present the technology at a physician networking and product introduction event in Buenos Aires on December 12, 2026, bringing together medical professionals, industry leaders and commercial partners.
“Argentina is becoming one of the most important markets in our international expansion strategy,” said Dave Christensen, CEO and President of Regenerative Medical Technology Group. “With Cellgenic’s expanding laboratory and commercial presence, we are building a platform that extends beyond traditional biologics distribution. Autologous fibroblast technology is an exciting addition to our aesthetic medicine pipeline, and our ambition is to establish Cellgenic as a leading force in the Argentine regenerative medicine market.”
The Company intends to support physician education, scientific collaboration and further product development in Argentina while continuing to expand its commercial infrastructure.
“Our strategy combines laboratory capabilities, a strong commercial organization and continuous physician education,” Christensen added. “As we introduce additional technologies, we expect Argentina to become an increasingly important contributor to Cellgenic’s international growth.”
About the Operating Division
Cellgenic is the advanced biologics and regenerative medicine commercialization division of Global Stem Cells Group, focused on cellular technologies, regenerative products and physician engagement. www.cellgenic.com
About RMTG
Regenerative Medical Technology Group, Inc. (OTC: RMTG) operates an integrated regenerative medicine platform through Global Stem Cells Group and its specialized businesses. www.rmtg.com
Forward-Looking Statements
This press release contains forward-looking statements under applicable securities laws, including statements regarding anticipated growth, revenues, product adoption, academic collaboration, product introductions and geographic expansion. Actual results may differ materially due to regulatory developments, operational execution, market acceptance, competition and other risks. These statements are not guarantees of future performance. The Company undertakes no duty to update them except as required by law.
Investor Relations
Regenerative Medical Technology Group, Inc. | OTC: RMTG | www.rmtg.com |
- Published in Press Releases
Cellular Hope Institute Expands International Patient Programs for U.S. and Canadian Markets
FOR IMMEDIATE RELEASE
- New premium, highly personalized international patient program targets individuals traveling from the United States and Canada
- Programs combine physician assessment, regenerative medicine, longevity technologies, diagnostics, and wellness services
- Expansion reflects growing North American interest in destination-based longevity medicine
MIAMI, FL — Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an expanded international patient strategy targeting individuals traveling from the United States and Canada to its Cancun facilities.
The institute is developing comprehensive, premium medical-wellness programs combining physician assessment, regenerative medicine, longevity technologies, diagnostics, and hospitality-oriented patient coordination where appropriate. The programs are intended for international patients seeking a highly personalized, destination-based longevity and regenerative medicine experience.
Cellular Hope Institute described the offering as a premium, highly personalized international patient program, reflecting the individualized nature of physician-directed longevity care rather than a standardized package.
“More patients in the U.S. and Canada are looking for a genuinely comprehensive longevity experience, not just a single procedure,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This program is built around that — physician assessment first, then a program built around the individual patient.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellular Hope Institute
Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), is based in Cancun, Mexico, and provides physician-directed regenerative medicine, longevity, and wellness programs to international patients.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
Cellular Hope Institute Expands Cancun Clinical Facilities and Longevity Platform
FOR IMMEDIATE RELEASE
- Expansion introduces additional physician-directed longevity, wellness, and complementary technology capabilities
- Investment builds on Cellgenic’s parallel laboratory expansion in the same city
- Cellular Hope Institute positions Cancun as a comprehensive destination for international regenerative medicine and longevity patients
MIAMI, FL — Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced a significant expansion of its clinical facilities in Cancun, Mexico, introducing additional physician-directed longevity, wellness, and complementary technology capabilities.
The expansion adds hyperbaric medicine, red-light/photobiomodulation therapies, PEMF, radiofrequency technologies, molecular hydrogen therapies, EBOO/EVO, and therapeutic plasma exchange (TPE) to the institute’s clinical capabilities.
The expansion is designed to create a more comprehensive destination for international patients seeking physician-directed regenerative medicine and longevity programs, and complements Cellgenic’s parallel laboratory expansion in the same city. Cellular Hope Institute was clear that all programs remain physician-directed and made no claims regarding specific health outcomes.
“Patients traveling internationally for longevity and regenerative medicine care want more than a single treatment — they want a comprehensive, physician-directed program,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This expansion is about building that in Cancun.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellular Hope Institute
Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), is based in Cancun, Mexico, and provides physician-directed regenerative medicine, longevity, and wellness programs to international patients.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Concludes 2026 International Conference Calendar in Dubai, December 4–5
FOR IMMEDIATE RELEASE
- Conference marks ISSCA’s return to Dubai, United Arab Emirates, December 4–5 at the Hyatt Regency Dubai Creek Heights
- Event closes ISSCA’s international conference calendar for the year
- Release quantifies the year’s countries reached and conferences held, with final physician-trained and certification totals confirmed at publication
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 129, its return to Dubai, United Arab Emirates, December 4–5 at the Hyatt Regency Dubai Creek Heights, closing ISSCA’s international conference calendar for the year.
The Dubai conference caps a year that included ISSCA events across more than a dozen countries — including Paraguay, Pakistan, Portugal, Brazil, the Dominican Republic, Peru, Argentina, Turkey, Mexico, Bolivia, and Colombia — alongside continued growth of its Online Academy and certification programs. Final totals for physicians trained and certifications issued across the year will be confirmed at time of publication.
ISSCA positioned Dubai as a fitting close to the calendar given the UAE’s role as a regional hub connecting Middle Eastern, South Asian, and African physician communities to ISSCA’s education network.
“Closing the year in Dubai lets us look back at a genuinely global conference calendar — Latin America, the Middle East, and everywhere in between,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “It’s also where we start planning next year’s expansion.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Returns to São Paulo for Second Brazil Congress, November 20–21
FOR IMMEDIATE RELEASE
- Second São Paulo congress of 2026 runs November 20–21, following ISSCA’s April program in the city
- Additional congress reflects Brazil’s position as one of ISSCA’s highest-priority Latin American markets
- Event runs alongside Cellgenic’s permanent operations launch in Brazil
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 127, its second São Paulo, Brazil congress of 2026, taking place November 20–21 in the city’s Vila Olímpia district, following ISSCA’s first 2026 Brazil program in April.
Running two Brazil events in a single year is a frequency ISSCA has not previously applied to the market, reflecting Brazil’s scale and the organization’s broader Latin American expansion alongside Cellgenic’s commercial buildout.
The second São Paulo congress runs alongside Cellgenic’s establishment of permanent operations in Brazil, reinforcing ISSCA and Cellgenic’s coordinated market presence in one of Latin America’s largest healthcare markets.
“Brazil earned a second date on our calendar this year,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Between ISSCA’s education programming and Cellgenic’s commercial buildout, Brazil is becoming one of our most active single markets anywhere in the world.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Announces Bogotá, Colombia Conference, November 27–28
FOR IMMEDIATE RELEASE
- Conference runs November 27–28 at the Hilton Bogotá Corferias, continuing ISSCA’s expansion of physician education throughout Latin America
- Program targets more than 250 physician attendees across flagship and peptide-medicine certification tracks
- Event complements Cellgenic’s parallel commercial expansion into Colombia
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 128, its conference in Bogotá, Colombia, taking place November 27–28 at the Hilton Bogotá Corferias.
The Bogotá conference continues ISSCA’s ongoing expansion of physician education throughout Latin America, with a program built around the organization’s flagship and peptide-medicine certification tracks. Confirmed faculty and full workshop programming will be published as the event date approaches.
The event runs alongside Cellgenic’s operational expansion into Colombia, reinforcing ISSCA and Cellgenic’s coordinated approach to entering new Latin American markets through both education and commercial channels.
“Bogotá gives ISSCA a direct connection to Colombia’s physician community right as Cellgenic is building out commercial operations there too,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “That kind of coordination is exactly the model we want to replicate.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Announces Santa Cruz, Bolivia Conference, October 23–24
FOR IMMEDIATE RELEASE
- New regenerative medicine conference set for Hotel Los Tajibos, Santa Cruz de la Sierra, October 23–24
- Event extends ISSCA’s physician education strategy further into Latin America
- Conference reflects continued regional demand for regenerative medicine training
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 126, its regenerative medicine conference in Santa Cruz de la Sierra, Bolivia, taking place October 23–24 at Hotel Los Tajibos.
The Santa Cruz conference extends ISSCA’s Latin American physician education strategy into a market the organization has not previously featured prominently in its conference calendar, complementing its established programming in Argentina, Brazil, and Colombia. The program includes ISSCA’s flagship and peptide-medicine certification tracks.
ISSCA said Bolivia represents continued regional demand for structured regenerative medicine training and reflects the organization’s strategy of expanding physician access market-by-market across Latin America.
“Every new country on ISSCA’s calendar represents physicians who didn’t have easy access to this kind of training before,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Bolivia is the next step in that expansion.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Introduces New Longevity and Adjunctive Therapies Certification
FOR IMMEDIATE RELEASE
- New program addresses complementary and adjunctive technologies increasingly used in longevity and regenerative medicine practices
- Curriculum spans therapeutic plasma exchange, peptide medicine, IV therapy, and additional physician-directed technologies
- Certification helps physicians understand how multiple technologies fit within a comprehensive medical practice
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced a new educational program focused on complementary and adjunctive technologies increasingly incorporated into longevity and regenerative medicine practices.
Curriculum areas include therapeutic plasma exchange (TPE), EBOO/EVO, peptide medicine, IV therapy, longevity medicine, artificial intelligence, PEMF, photobiomodulation/red-light technologies, hyperbaric medicine, and other physician-directed complementary technologies.
ISSCA said the program is designed to help physicians understand how multiple adjunctive technologies may fit within a comprehensive medical practice, rather than certifying any single modality in isolation.
“Physicians aren’t choosing between one technology and another anymore — they’re building comprehensive practices,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This certification is designed around that reality.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases











